1. Introduction {#s0005}
===============

Poor cardiovascular health (CVH) is associated with an increased risk for cardiovascular ([@bb0070], [@bb0050], [@bb0165], [@bb0115]) and other chronic diseases ([@bb0135]). CVH is amenable to change via prevention efforts ([@bb0135], [@bb0015], [@bb0055]). Population-level approaches to reduce tobacco use and promote healthy dietary choices ([@bb0045]) are needed to achieve the American Heart Association\'s (AHA\'s) goal of "improving the CVH of all Americans 20% by 2020" ([@bb0140]). Prevention discussions at the point-of-care and early CVH interventions in the primary care setting may enhance and reinforce population-level strategies to improve CVH for all Americans ([@bb0160]).

The increasing need for high-quality, patient-centered documentation at the point-of-care places time constraints on primary care providers, thus limiting behavior modification counseling during a patient encounter ([@bb0080], [@bb0100]). Evidence suggests that patient-centeredness decreases as providers increase attention to an electronic health record (EHR) ([@bb0185]). In fact, primary care providers spend almost as much time documenting the encounter as they do in direct patient care ([@bb0010]). Further, CVH data are often located on various screens throughout the EHR, limiting the ability of care providers to synthesize and reason upon such data, particularly in time-constrained practice settings. Compounding this problem, many providers lack training in delivering prevention messages and supporting behavior change ([@bb0120], [@bb0075]). In a similar manner, few current EHR platforms provide tailored healthcare communication functionality as an alternative to shared decision-making ([@bb0150], [@bb0155], [@bb0035]). As a result of these barriers, few providers discuss physical activity or other lifestyle changes with patients nor do patients receive adequate information support to enable or promote such healthy behaviors ([@bb0040]).

Clinical decision support (CDS) within EHR systems helps providers with decision-making tasks about individual patients at the point-of-care ([@bb0030]), and modifies provider behavior by recommending specific actions or reminding providers of clinical care guidelines ([@bb0175]), prompts smoking cessation counseling and referrals ([@bb0180]), facilitates goal-setting among pre-diabetics ([@bb0035]), lowers cholesterol ([@bb0190]), and increases appropriate prescribing ([@bb0130]). There is growing consensus for improved patient outcomes through implementation of EHR tools in cardiothoracic surgery ([@bb0170]), specialty clinics, and primary care ([@bb0190]).

In response to the preceding challenges and opportunities, we developed and evaluated a novel, easy-to-use, EHR-based CVH assessment tool for use in primary care that automatically populates with EHR data and renders an interactive visual display of a patient\'s CVH score ([@bb0060]). We hypothesized that the CVH of patients with access to our CVH tool would improve over a one-year period, while the CVH of patients without access to the tool would stay the same or worsen.

2. Material and methods {#s0010}
=======================

As we have described previously ([@bb0060]), the stroke prevention in healthcare delivery environments (SPHERE) tool was developed and implemented in the outpatient EHR of a general internal medicine clinic at The Ohio State University Wexner Medical Center (OSUWMC) ([@bb0060]). Briefly, the SPHERE tool ([Supplementary Figure](#ec0005){ref-type="supplementary-material"}) was designed to increase patient-provider communication around prevention. The SPHERE tool launches within the EHR during a patient encounter, and is viewable by both patient and provider. The provider uses the interactive features of the tool (slider bars and buttons) to show how changes in each CVH component can impact their overall CVH. Providers in the intervention clinic were not incentivized to use the tool; details on its use are presented in a separate publication ([@bb0065]).

Our eligible patient population included women who were 65 years of age or older at the time of the baseline encounter. Control clinic patients were seen in a different outpatient clinic in the OSUWMC system, and received usual care with regard to prevention discussions. The study, with a waiver of informed consent, was approved by The Ohio State University\'s Institutional Review Board (approval number 2013H0083).

Baseline demographic and CVH data for the eligible patient population at both clinics were obtained from the EHR for the time period of May 1, 2013 through July 31, 2013. The SPHERE tool was accessible to providers in the intervention clinic beginning October 6, 2013. Follow-up CVH data were queried one-year later for encounters occurring between May 1, 2014 and July 31, 2014. We conducted a group-level analysis on the subset of women seen in the intervention clinic (n = 109) and women seen in the control clinic (n = 42) who had an encounter during both time periods. We also report on the CVH of all eligible patients seen during baseline and/or follow-up periods. Baseline data indicated that 160 eligible patients were seen in the intervention clinic, and 62 eligible patients were seen in the control clinic. Follow-up data collection yielded 168 eligible intervention patients and 96 eligible control patients.

Baseline and follow-up data included the demographic variables of age and race (white, black, other). We used the most recent data (collected within the past 12 months) to characterize smoking status, body mass index (BMI), total cholesterol, blood pressure, and fasting glucose/hemoglobin A1c. Two other components of CVH, physical activity and diet, were infrequently entered as unstructured data in clinic notes, and were not computationally actionable as free text. Therefore, we excluded these two variables from the current study report.

We assigned patients to ideal, intermediate, and poor categories of the AHA\'s CVH metric as shown in [Table 1](#t0005){ref-type="table"}, based on values associated with each of the biometric components, with the exception of fasting glucose/hemoglobin A1c ([@bb0005]). For fasting glucose, we categorized participants into ideal (not taking glucose-lowering medication) and intermediate (taking glucose-lowering medication) CVH categories due to high levels of missing data for both fasting glucose and hemoglobin A1c laboratory values in our EHR.

2.1. Statistical methods {#s0015}
------------------------

Demographic factors in both control and intervention clinic were characterized as mean (SD) for continuous variables and as proportions for categorical variables. For each of the five CVH categories, the proportion of women in each clinic in each category (e.g., ideal, intermediate, or poor health or missing) was reported both at baseline and post-intervention. Overall CVH score, calculated as 2 points for idea, 1 point for intermediate, and 0 for poor on each of the five available factors was calculated for each participant and the change in average CVH score in aggregate (pre-post) for each clinic was estimated using a GEE approach to account for correlations on women measured during both periods. The main analysis comprised the subset of women who were observed during both baseline and follow-up periods. A secondary analysis investigated changes among all eligible women seen during baseline and/or follow-up.

Data analysis was conducted using STATA (StataCorp). Statistical significance was set at 0.05.

3. Results {#s0020}
==========

At baseline, the average age of the subset of patients seen in the intervention clinic was 75 years, while the average age was 72 in the control clinic ([Table 2](#t0010){ref-type="table"}). Differences were seen at baseline by race between the intervention (35% black) and control (21% black) clinics. The demographic data in the intervention clinic did not change appreciably between the baseline and follow-up periods in either clinic. The baseline data of all eligible women seen during the baseline and/or follow-up periods in the intervention clinic had a similar distribution of demographic factors compared to the subset of patients at baseline. Similarly, the subset of patients in the control clinic had nearly equivalent demographic characteristics compared to all eligible women seen during the baseline and/or follow-up periods in the control clinic ([Table 2](#t0010){ref-type="table"}).

Among women in the intervention clinic who were seen during both the baseline and follow-up periods, we observed CVH improve on the metrics of BMI (14.7 to 19.3% ideal) and diabetes (56.9 to 62.4% ideal) from baseline to follow-up. Meanwhile, the CVH of women in the control clinic either held constant (diabetes; 83.3% ideal) or worsened slightly (BMI; 23.8 to 19.0% ideal) from baseline to follow-up.

At baseline, a greater proportion of all eligible patients in the intervention clinic ([Fig. 1](#f0005){ref-type="fig"}C) were in ideal CVH compared to those in the control clinic ([Fig. 1](#f0005){ref-type="fig"}D) for current smoking and total cholesterol. However, eligible patients in the intervention clinic were more likely to be in poor CVH for BMI and blood pressure, and to be treated for diabetes, compared to the control clinic. Among all eligible patients in the intervention clinic, improvements were seen from baseline to follow-up for BMI (18.1 to 20.2% ideal) and diabetes status (59.4 to 63.7% ideal).

Average overall CVH score increased by 0.024 (95% CI: − 0.24 to 0.29) in the intervention clinic (p = 0.86), indicating that improvements in BMI and diabetes were somewhat offset by losses on other factors. Conversely, CVH components either held constant or worsened among eligible patients seen in the control clinic. In the control clinic, the estimated change in total CVH score was 0.018 (95% CI: − 0.40 to 0.44).

4. Discussion {#s0025}
=============

In this relatively small sample of patients, we noted improvements in CVH, which has important clinical implications for the prevention of chronic disease ([@bb0135]). In particular, the SPHERE tool\'s focus on improving the CVH of patients in primary care is consistent with prevention services covered by the Affordable Care Act. These services include blood pressure, cholesterol, and diabetes screening; diet counseling; obesity screening and counseling; and tobacco screening and cessation support. As a result, the use of a CDS tool with a focus on prevention, like SPHERE, is responsive to the Stage 2 Meaningful Use criteria for EHRs ([@bb0085], [@bb0090], [@bb0095]).

The SPHERE tool, by design, brings lifestyle factors into the workflow of patient care. As a result, the EHR becomes less of a passive data capture system as is typically the case, and instead, serves as the basis for timely and efficient shared decision-making. Shared decision-making allows for patients\' values, needs, and preferences to guide evidence-based care ([@bb0025]), and our EHR systems should help improve shared decision-making around prevention of chronic disease ([@bb0110]). A Cochrane review of interventions for improving the adoption of shared decision making concluded that interventions targeting the provider and patient were more effective than those targeting the provider or patient alone ([@bb0125]).

To that end, providers need easy-to-use tools at the point-of-care to help patients improve CVH, as \< 3% of Americans described in population-based studies are in ideal CVH according to AHA\'s metric ([@bb0070], [@bb0050], [@bb0115], [@bb0105], [@bb0020]). We demonstrated that the EHR could deliver such a tool using an existing AHA framework designed to improve CVH ([@bb0140]). The success of the tool is due to ease of use, seamless integration with clinical workflow, functionality within the EHR window, non-intrusive design, and the automatic rendering of a CVH calculation at the point-of-care to improve patient-provider communication around CVH ([@bb0065]).

A unique strength of the study was the use of an intervention clinic that was located in an underserved area of our community with a more racially diverse patient population as compared to the control clinic ([@bb0060]). Our results add to a paucity of literature that demonstrates improvements in CVH using EHR-based tools ([@bb0145]). Unlike existing research, our study was done in a primary care setting and targeted all patients meeting age and clinic criteria, regardless of presence of comorbid conditions. Also distinct from other point-of-care interventions, the SPHERE tool is designed to be platform-independent and scalable to other patient populations and healthcare settings, not to mention EHR platforms ([@bb0060], [@bb0110]).

Limitations of this initial study stem primarily from the limited number of observations for older women seen in two outpatient clinics at baseline and again at one-year follow-up. Our data do not describe how many women initiated evidence-based treatment or who had laboratory assessments ordered as a result of their primary care encounter. In addition, diet and physical activity data were not recorded in the EHR. While we collected these data via the patient-facing EHR portal (56% response rate), these data were only collected at follow-up, not at baseline ([@bb0060]). In addition, we were unable to detect changes in smoking behavior in the intervention clinic due to an already high prevalence of ideal smoking behavior in this clinic and the small sample size included in both baseline and follow-up periods.

Our study overlapped with another clinic-level intervention which targeted obese patients in the intervention clinic. The goal of that study was to encourage eligible patients to talk to their provider about their weight via an educational video. The medical assistant was to play the video for the patient while they waited for their provider in the exam room prior to their appointment. Of the patients eligible for that study, queried from the EHR from May 2012 through April 2013, 36 were females 65 years of age and older. Since the results of that study are not available, we cannot comment on the proportion of those 36 women who were shown the video while they waited for their provider, and whether they were the same women who were also eligible for the SPHERE study during a similar time period.

5. Conclusions {#s0030}
==============

This is the first study to develop and implement an EHR-based CVH visualization tool. Our study demonstrates that it is feasible to implement patient-centered EHR-based tools at the point-of-care in the primary care setting. Our work answers the call for next-generation EHR design to facilitate patient-provider communication ([@bb0185]). The SPHERE study is a unique multidisciplinary collaboration aimed at addressing the feasibility of using a system embedded in the EHR to improve patient-centered care. Future work is needed to assess how to best harness the potential of such tools in order to have the greatest impact on the CVH of a patient population.
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Changes in CVH from baseline (May--July 2013) to follow-up (May--July 2014) in the OSUWMC (A) intervention and (B) control clinics: patients seen in both baseline and follow-up periods. Changes in CVH from baseline to follow-up in the (C) intervention and (D) control clinics: patients seen in baseline and/or follow-up periods.
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###### 

Measures of CVH according to the American Heart Association ([@bb0140]), and cut points used for hemoglobin A1c ([@bb0005]).

Table 1

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                      Poor health                                    Intermediate health                                                    Ideal health
  ------------------- ---------------------------------------------- ---------------------------------------------------------------------- ----------------------------
  Smoking status      Yes                                            Former ≤ 12 months                                                     Never or quit \> 12 months

  Body mass index     ≥ 30 kg/m^2^                                   25--29.9 kg/m^2^                                                       \< 25 kg/m^2^

  Total cholesterol   ≥ 240 mg/dL                                    200--239 mg/dL or treated to goal                                      \< 200 mg/dL

  Blood pressure      Systolic ≥ 140 mm Hg or Diastolic ≥ 90 mm Hg   Systolic 120--139 mm Hg or Diastolic 80--89 mm Hg or treated to goal   Systolic \< 120 mm Hg\
                                                                                                                                            Diastolic \< 80 mm Hg

  Fasting glucose     ≥ 126 mg/dL                                    100--125 mg/dL or treated to goal                                      \< 100 mg/dL

  Hemoglobin A1c      ≥ 6.5%                                         5.7--6.4% or treated to goal                                           \< 5.7%
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Demographic characteristics of all eligible patients seen at baseline (May--July, 2013) and follow-up (May--July 2014): OSUWMC.

Table 2

             Intervention clinic   Control clinic                                          
  ---------- --------------------- ---------------- ------------ ------------ ------------ ------------
  N          160                   168              109          62           96           42
  Age (SD)   74.2 (6.7)            74.5 (7.0)       75.0 (6.8)   72.8 (7.5)   71.6 (6.7)   72.4 (7.4)
  Race                                                                                     
   White     93 (59%)              96 (57%)         64 (59%)     45 (73%)     76 (79%)     30 (71%)
   Black     56 (35%)              62 (37%)         38 (35%)     12 (19%)     14 (15%)     9 (21%)
   Other     9 (6%)                9 (5%)           6 (6%)       5 (8%)       6 (6%)       3 (7%)

Subset comprises patients seen in both baseline and follow-up periods.
